Author name: Jaspreet Singh Arora

Jaspreet Singh Arora is the Chief Investment Officer at Equentis, where he heads a seasoned team of equity analysts and turns two decades of market experience into portfolios that consistently beat the benchmark. A go-to voice on cement, building-materials, real-estate, and construction stocks, Jaspreet previously ran research desks at leading brokerages, honing an eye for the metrics that truly move share prices. His plain-spoken analysis helps investors cut through noise and act with conviction. When he’s not deep-diving into earnings calls, you’ll find him unwinding over sports, weekend cricket or a good history podcast.

Hyundai Motor Shares Beyond IPO Post Trending Blog 00 01
News, IPO - Blog Category

Export Optimism Lifts Hyundai Motor Share Price. What’s Next?

India’s benchmark indices have been closing in green for the past couple of trading sessions. 
Thanks to the easing RBI policy and the progress in US-India trade talks, the Nifty 50 index has reached an eight-month high, while the BSE Sensex has climbed to 82,400 levels.

Alongside the rally in the overall market, a stock that has caught investor’s attention is Hyundai Motor. Hyundai Motor share price has crossed its IPO price for the first time since listing. 
So, what’s driving the rally? Can the rally pick up momentum? Let’s take a closer look…

Aegis Vopak Terminals IPO Post Trending Blog 00 01
News, IPO - Blog Category

Aegis Vopak Terminals IPO: GMP, Issue Size, and 5 Key Things to Know

Aegis Vopak Terminals Limited is all set to open its ₹2,800 crore IPO for subscription, drawing interest from investors tracking the infrastructure and energy logistics sector. The company operates strategically located storage terminals across major Indian ports, catering to petroleum products, LPG, and industrial chemicals. With a solid anchor book, a notable grey market premium (GMP), and a strong operational footprint, the IPO is one of the key offerings this week. Here’s a detailed look at the issue size, share allocation, GMP, company background, financials, and a SWOT analysis to help you evaluate the opportunity.

Emcure Pharma Shares Surge In the Last Two Sessions
News, Business - Blog Category

Namita Thapar’s Emcure Pharma Up 20% After 63% Profit Growth in Q4

As the markets continued to be in high spirits today with the primary indices running green for the trading session, another stock made it to the limelight with an approximate 20% gain over the last two trading sessions. Emcure Pharma shares hit the upper circuit on 23rd May 2025 as the company announced a nearly 63% increase in the consolidated net profit for FY2025 Q4. What propelled the profit figures? How much did the shares soar for the day? Let’s understand.